Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Understanding eligibility criteria for clinical trials to increase study size

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 407

Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia

Dr R. Donald Harvey talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study looking at aNSCLC patients from ASCO’s CancerLinQ database and understanding their eligibility criteria.

He explains that three main areas were considered in the criteria: the presence or absence of brain metastases, prior or concurrent history of additional cancer diagnosis and the renal function.

Dr Harvey reports that the percentage of patients excluded was 47.7% for the older, restrictive criteria and 1.5% when the criteria was taken away.

Watch the press conference here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation